Abstract
The apolipoprotein AI-Milano (AI-M) has been the first described molecular variant of human apolipoproteins (1,2). It is characterized by a cysteine for arginine substitution at the position 173 in the primary sequence of apo AI (3), leading to the formation of disulphide bonded homodimers AI-M/AI-M and heterodimers with apolipoprotein AII (AI-M/AII) (2).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G. Franceschini, C. R. Sirtori, A. Capurso, K. H. Weisgraber and R. W. Mahley, AI-Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family, J. Clin. Invest., 66: 892 (1980).
K. H. Weisgraber, T. P. Bersot, R. W. Mahley, G. Franceschini and C. R. Sirtori, AI-Milano apoprotein. Isolation and characterization of a cysteine-containing variant of the AI apoprotein from human high density lipoproteins, J. Clin. Invest., 66: 901 (1980).
K.H. Weisgraber, S.C. Rail Jr, T.P. Bersot, R.W. Mahley, G. France¬schini and C.R. Sirtori, Apolipoprotein AI-Milano. Detection of normal AI in affected subjects and evidence for a cysteine for arginine substitution in the variant AI, J. Biol. Chem., 257: 9926 (1983).
R.W. Mahley, T.L. Innerarity, S.C. Rail Jr and K.H. Weisgraber, Plasma lipoproteins: apolipoprotein structure and function, J. Lipid Res., 25: 1277 (1984).
G. Franceschini, C.R. Sirtori, E. Bosisio, V. Gualandri, G.B. Orsini, A.M. Mogavero and A. Capurso, Relationship of the phenotypic expression of the AI-Milano apoprotein with plasma lipid and lipoprotein levels, Atherosclerosis, 58: 159 (1985).
V. Gualandri, G. Franceschini, C.R. Sirtori, G. Gianfranceschi, G.B. Orsini, A. Cerrone and A. Menotti, AI-Milano apoprotein. Identification of the complete kindred and evidence of a dominant genetic transmission, Amer. J. Human. Gen., 37: 1083 (1985).
G. Franceschini, G. Vecchio, G. Gianfranceschi, D. Magani and C.R. Sirtori, Apolipoprotein AI-Milano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant, J. Biol. Chem., 260: 16321 (1985).
A. Bierzynski, P.S. Kim and R.L. Baldwin, A salt bridge stabilizes the helix formed by isolated C-peptide of RNase A, Proc. Natl. Acad. Sci. USA, 79: 2470 (1982).
J.P. Segrest and R.J. Feldmann, Amphipathic helixes and plasma lipoproteins: a computer study, Biopolymers, 16: 2053 (1977).
G. Franceschini, L. Calabresi, P. Apebe, M. Sirtori, G. Vecchio and C.R. Sirtori, Apolipoprotein AI-Milano: a structural modification in an apolipoprotein variant leading to unusual lipid binding properties, in: Human apolipoprotein mutants: impact on atherosclerosis and longevity (C.R. Sirtori, A.V. Nichols and G. Franceschini, eds), Plenum Press, N.Y., p. 71 (1986).
H.B. Brewer Jr, G. Ghiselli, E.J. Shaefer, L.A. Zech, G. Franceschini and C.R. Sirtori, Apolipoprotein AI-Milano: in vivo metabolism of an apolipoprotein AI variant, in: Human apolipoprotein mutants: impact on atherosclerosis and longevity (C.R. Sirtori, A.V. Nichols and G. Franceschini, eds), Plenum Press, N.Y., p. 95 (1986).
C.J. Fielding, V.G. Shore and P.E. Fielding, A protein cofactor of lecithin:cholesterol acyltransferase, Biochem. Biophys. Res. Comm., 46: 1493 (1972).
N.H. Fidge, Partial purification of a high density lipoprotein-binding protein from rat liver and kidney membranes, FEBS Lett., 199: 265 (1986).
G. Utermann, J. Haas, A. Steinmetz, R. Paetzold, S.C. Rail Jr, K.H. Weisgraber and R.W. Mahley, Apolipoprotein AI-Giessen: a mutant that is defective in activating lecithin:cholesterol acyltransferase, Eur. J. Biochem., 144: 325 (1984).
S.C. Rail Jr, K.H. Weisgraber, R.W. Mahley, Y. Ogawa, C.J. Fielding, G. Utermann, J. Haas, A. Steinmetz, H.J. Menzel and G. Assmann, Abnormal lecithin:cholesterol acyltransferase activation by a human apoli-poprotein AI variant in which a single lysine residue is deleted, J. Biol. Chem., 259: 10063 (1984).
A. Jonas., Synthetic substrates of lecithin:cholesterol acyltransferase, J. Lipid Res., 27: 689 (1986).
G. Franceschini, T.G. Frosi, C. Manzoni, G. Gianfranceschi and C.R. Sirtori, High density lipoprotein-3 heterogeneity in subjects with the apo AI-Milano variant, J. Biol. Chem., 257: 9926 (1982).
G. Franceschini, L. Calabresi, C. Tosi, C.R. Sirtori, C. Fragiacomo, G. Noseda, E. Gong, P. Blanche and A.V. Nichols, Apolipoprotein AI- Milano: correlation between high density lipoprotein subclass distribution and triglyceridemia, Arteriosclerosis, 7: 426 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Plenum Press, New York
About this chapter
Cite this chapter
Franceschini, G., Calabresi, L., Baio, M., Nichols, A.V., Sirtori, C.R. (1989). Apolipoprotein AI-Milano: Mechanisms for the Antiatherogenic Potential. In: Sirtori, C.R., Franceschini, G., Brewer, H.B., Assmann, G. (eds) Human Apolipoprotein Mutants 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9549-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-9549-6_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-9551-9
Online ISBN: 978-1-4615-9549-6
eBook Packages: Springer Book Archive